Navigation Links
Sangamo BioSciences Announces Presentation At The 2014 Wedbush Securities Life Sciences Management Access Conference
Date:8/6/2014

RICHMOND, Calif., Aug. 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:40 pm ET on Tuesday, August 12, 2014, at the 2014 Wedbush Life Sciences Management Access Conference.  The conference is being held in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases.  The company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Reports First Quarter 2012 Financial Results
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
8. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Protocol Networks brings independent technology ... of brand-neutral, independent consultants, Protocol Networks has recently announced ... over the years, his company has attracted several clients ... Plainfield, as well as others. With the success of ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Trials for Tengion Neo-Bladder(TM) Franchise , ... Tengion Inc. , a clinical stage regenerative medicine ... today announced that it has completed a second closing ... approximately $21 million in additional equity capital from the ...
... Nov. 19 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... for the early detection of diseases and personalized ... Canadian Colorectal Cancer Advisory Board. Drs. Lawrence Cohen, ... Barry Stein will advise GeneNews on clinical and ...
... a campaign,to significantly reduce the most common cancer affecting ... or SSA) has announced it is,launching the first phase ... (HPV), the primary cause of cervical cancer, to low-income,women ... covered by the agency. In,the first phase of the ...
Cached Biology Technology:Tengion Announces Second Closing of Series C Financing 2Tengion Announces Second Closing of Series C Financing 3GeneNews appoints Canadian Colorectal Cancer Advisory Board 2GeneNews appoints Canadian Colorectal Cancer Advisory Board 3Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer 2Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer 3Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer 4Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer 5
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Department of Energy,s (DOE) Argonne National Laboratory lead ... 65 million hours of computing time on Argonne,s ... conduct advanced simulation and analysis, performing virtual experiments ... the natural world. They will also develop scalable ...
... why a tuberculosis vaccine is not as effective for some ... not work as well for some as they do for ... issue of the Journal of Leukocyte Biology ( ... common environmental bacterium found in soil and water, can decrease ...
... major new study shows that a pregnant mother,s diet not ... physically changes the brain directly impacting what the infant eats ... importance of eating a healthy diet and refraining from drinking ... conducted the two-year study while a visiting scientist at the ...
Cached Biology News:Argonne scientists awarded supercomputing time to enable scientific breakthroughs 2Argonne scientists awarded supercomputing time to enable scientific breakthroughs 3Argonne scientists awarded supercomputing time to enable scientific breakthroughs 4Blame the environment: Why vaccines may be ineffective for some people 2Study shows pregnant mother's diet impacts infant's sense of smell 2
... Microarrays designed for DNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
... Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... the use of small interfering RNA (siRNA) ... RNA interference (RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be ... and then transfected into the target cells ...
... The 820-MS features Varians unique ... provides simple, routine removal of troublesome ... more flexible interference-free analysis without the ... quadrupole ion guides, or cells. And, ...
Biology Products: